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consent patients who had been hospitalized for ACS and are on
Ticagrelor on discharge or on Ticagrelor therapy for ≤1 month will
be enrolled in the study and followed up for a period of 12 months.
Demographic data, diagnosis (type of ACS), management of ACS,
laboratory investigations, relevant history, and physical examina-
tion will be collated.
Results: Study is expected to ﬁll a signiﬁcant gap existing in our
knowledge to understand the usage pattern of Ticagrelor in real life
scenario in large number of ACS patients in India. The aim of this
national study is to understand the usage pattern (including the
durationof treatment) of Ticagrelor invariousACSpatientpopulation
undergoingPCI,CABG,ormedicalmanagement ina real-lifesetting in
India.Moreover,patientswithvarious risk factors (i.e. elderlypatients,
diabetes, renal impairment, smoking, GRACE risk score) and their
association with ACS and Ticagrelor usage will be measured.
The study started in May 2015 and approximately 100 patients
have been enrolled till date.
Conclusion: The multicenter national study will allow generating
real life evidence by involving patients from different geographies
and healthcare systems in India. The study is intended to provide
useful evidence of the Ticagrelor usage in variety of ACS patients in
actual hospital settings.
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Background: SYNTAX score is an objective scoring system to assess
severity and extent coronary artery disease. To evaluate the prognos-
tic value of the SYNTAX score in predicting in-hospital mortality in
coronary artery bypass patients, at a tertiary centre in India.
Methods: A cohort of 325 patients who underwent coronary artery
bypass surgery were included in this study from July 2012 to May
2014. They were divided into tertiles according to the SYNTAX
score (0–22, 23–33, and above 33). The endpoint was in-hospital
mortality.
Results: The mortality in SS tertiles were as follows: 0–22 = 6%; 23–
33 = 4.2%, and above 33 = 14.3%. There was signiﬁcant increase in
mortality in the third tertile ( p = 0.0297). SS above 33 had an odd's
ratio of 3.036 ( p = 0.018) for mortality.
Conclusion: Severity of coronary artery disease as measured by SS
of more than 33 is a signiﬁcant predictor of mortality after CAB
surgery.
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Background: Platelet activation and aggregation has been
implicated in the pathogenesis of atherosclerosis and in the
development of acute thrombotic event. Platelet volume is a mar-
ker of platelet activation and function, and is measured using
mean platelet volume (MPV).
Aim: To investigate the relationship between MPV and angio-
graphic severity of coronary artery disease in terms of SYNTAX
score, both in stable angina and acute coronary syndromes.
Methods: In this study, a total of 160 patients were evaluated who
presented with suspected CAD on clinical grounds. All patients
underwent routine biochemical examination, complete blood
count, and coronary artery angiography using standardized pro-
tocol. SYNTAX score was calculated using online software and
correlation between MPV and coronary lesion severity was ana-
lysed using statistical software.
Results: Out of 160 patients, 37 (23.12%) patients presented with
CSA and 104 (65%) patients with ACS; out of which 29 (18.12%)
patients diagnosed with UA or NSTEMI and 75 (46.87%) patients
with STEMI; 19 (11.87%) patients had normal coronary angio-
gram, allocated to control group. Mean age of the CSA patients
was 58.16  11.48 years, while in UA&NSTEMI and STEMI group it
was 52.10  8.52 years and 53.99  11.83 years, respectively.
51.21  9.43 years was the mean age in control group. 129
(80.6%) patients were male and 31 (19.4%) patients were female.
ACS patients, i.e. UA&NSTEMI and STEMI patients had signiﬁ-
cantly higher MPV value than CSA and control group (8.86  1.07,
8.83  0.73 fL vs 8.42  0.81, 7.50  0.18 fL; p < 0.001). Mean SYN-
TAX score in CSA group was 16.54  8.10 in male and 17.83  7.41
in female; in UA&NSTEMI group, 19.27  9.85 in male and 9.92
 9.89 in female with p value of 0.049. In STEMI group mean
SYNTAX score was 19.73  7.27 in male and 17.75  2.79 in
female. In low SYNTAX score group MPV values were signiﬁ-
cantly more in UA&NSTEMI patients and STEMI patients than
CSA and control group (8.37  0.76, 8.59  0.62 fL vs 8.09  0.62,
7.50  0.18 fL; p < 0.001). In intermediate and high SYNTAX score
group MPV did not differ signiﬁcantly. MPV was signiﬁcantly
more in intermediate and high SYNTAX score category than low
SYNTAX score, in all the three study groups. According to Pear-
son correlation analysis there was large positive relationship
between MPV and SYNTAX score in all the three study groups.
ROC curve analysis showed cut-off values of MPV for predicting
the severity of SYNTAX score, were >7.7 fL for CSA group and
>8 fL for ACS patients.
Conclusion: We found that higher MPV values are signiﬁcantly
associated with acute coronary syndromes than stable angina;
higher the MPV value more severe and complex is the coronary
artery disease, as demonstrated by the SYNTAX score analysis.
MPV can be considered a marker of platelet reactivity or a risk
factor for CAD. Large scale, randomized controlled trials are
needed for further clariﬁcation.
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Background: Postinfarction angina is not an uncommon complica-
tion after myocardial infarction (MI). Because of its high risk score
(Unstable Angina class III, Risk score 9 if rest angina <48 h post MI)
guidelines recommend early intervention in these patients. How-
ever, ﬁnancial constraints and lack of wide insurance coverage in
developing countries prohibit intervention in these patients. That
is why we analysed the addition of tiroﬁban (GpIIb/IIIa inhibitor)
which acts by inhibiting platelet aggregation a key mechanism in
postinfarction angina.
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Objective: To study role of tiroﬁban in postinfarction angina who
refused for early intervention.
Methodology: (1) Single centre prospective trial. (2) Duration of
study – December 2013 to June2015. (3) Total of 212 patients of
postinfarction angina who refused to undergo early intervention
after thrombolysis included in this study. (4) Follow up for 30 days.
(5) They are assigned in 1:1 manner to receive either tiroﬁban
intravenously 25 mg/kg over 3 min and then 0.15 mg/kg/min (or
0.075 mg/kg/min for patients with serum creatinine >1.5 mg%),
for up to 18 h along with intensiﬁcation of antianginal therapy
(group A – 106 patients) OR intensiﬁed antianginal therapy alone
(group B – 106 patients). (6) Patients were well matched according
to baseline characteristics.
Inclusion criteria: (1) Written informed consent. (2) Patients with
STEMI (anterior and inferior both) presenting in emergency within
12 h of chest pain thrombolysed exclusively with Streptokinase
(stk+) who had recurrent episodes of angina within 48 h of admis-
sion.
Exclusion criteria: (1) Hypersensitivity, history of thrombocytope-
nia with tiroﬁban. (2) Active/history of internal bleeding (within
last 30 days), intracranial hemorrhage, or neoplasm. (3) History of
stroke within last 30 days or any history of hemorrhagic stroke. (4)
AV malformation or aneurysm, aortic dissection, severe HTN,
acute pericarditis. (5) Current use of another parenteral glycopro-
tein IIb/IIIa inhibitor. (6) Patient age <18 yrs and >75 yrs.
Primary endpoints: Composite of all cause mortality and nonfatal
myocardial infarction at 30 days.
Secondary endpoints: (1) Recurrent episodes of angina. (2) Total
time to reach pain free status.
Results: Primary composite endpoints did not differ between 2
groups – 20 patients (18.86%) versus 21 patients (19.81%) reached
primary endpoints in groupAand group Bwith p value of 0.26, odds
ratio (OR) 0.82. Recurrent angina was lower in group A – 10 patients
(9.43%) versus 21 patients (19.81%) with p value of 0.003. Total time
to reach pain free status was lower in group A when compared to
group B with p value of 0.05 mean time of 18 hrs and 30 min in
group A as compared to 43 hrs and 18 min in group B. Minor
bleeding were higher with tiroﬁban (16.98% in group A versus
7.54% in group B) with p value 0.003 according to GUSTO bleeding
classiﬁcation. However more serious bleed did not differ between
two groups.
Conclusion: (1) Patients with postinfarction angina, unwilling
for intervention, had reduced incidence of recurrent angina
and earlier relief of anginal symptoms, when tiroﬁban added to
intensiﬁed antianginal therapy. (2) This is achieved without caus-
ing signiﬁcant difference in primary composite endpoint. (3)
Although signiﬁcant increase in minor bleed is noted, incidence
of major bleed did not differ between two groups.
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Background: (1) Following percutaneous coronary intervention
(PCI), clopidogrel therapy in addition to aspirin leads to greater
protection from thrombotic complications than aspirin alone.
Whether triple antiplatelet therapy with addition of cilostazol is
superior or similar to dual antiplatelet therapy in patients with
acute coronary syndrome undergoing PCI in the era of drug-eluting
stents remains unclear. (2) It inhibits platelet aggregation and is a
direct arterial vasodilator. Its main effects are dilation of the
arteries supplying blood to the legs and decreasing platelet coa-
gulation. (3) Because of its differentmechanism of action cilostazol
may have add on antiplatelet effect in patients undergoing PCI.
Objectives: To evaluate the effect of triple antiplatelet versus dual
antiplatelet therapy in patients with acute coronary syndrome
after PCI.
Inclusion criteria: Patients 18 years and above acute coronary
syndrome STEMI (AWMI & IWMI both) presented in emergency
within 12 h of chest pain.
Exclusion criteria: Contraindication to aspirin, clopidogrel, cilos-
tazol, left main disease, graft vessel disease, LVEF <30%.
Methods: We collected consecutive 280 acute coronary syndrome
patients between December 2013 and June 2015 undergoing drug-
eluting stents implantation in our hospital. They received either
dual (aspirin plus clopidogrel; dual group; n = 140) or triple (aspirin
plus clopidogrel plus cilostazol; triple group; n = 140) antiplatelet
therapy. Patients were well matched according to baseline char-
acteristics. The triple group received additional cilostazol at least
for 1 month. Various major adverse cardiac events at 6 months
were compared between these 2 groups.
Primary endpoints: Total deaths, cardiac deaths, and MACC.
Secondary endpoints: (1) Ischemia driven target lesion revascular-
isation and ischemia driven target vessel revascularisation at 6
months (2) Stent thrombosis.
Results: (1) Patientswith STEMIwho underwent primary PCIwith a
drug-eluting stent, after 6months of treatment, the group assigned
to cilostazol in addition to dual antiplatelet therapy for at least one
month (n = 35) had reduced cardiac death (adjusted OR = 0.52; 95%
CI, 0.32–0.84), p value – 0.04, total death (adjusted OR = 0.6; 95% CI,
0.41–0.89) p value – 0.02, and total major adverse cardiac events
(adjusted OR = 0.74; 95% CI, 0.58–0.95). (2) Incidence of TLR & TVR
did not decrease signiﬁcantly with p values 0.52 and 0.45, respec-
tively. (3) However, incidence of stent thrombosis reduced but
results were not signiﬁcant with p value 0.09. (4) The ﬁndings
supported the safety of triple antiplatelet therapy, as the adverse
effect proﬁle of the triple antiplatelet therapy group was not sig-
niﬁcantly different from that of the dual antiplatelet therapy group
(major bleedings: 2.1% in the cilostazol group vs. 2.8% in the dual
therapy group). (5) Patients who beneﬁted the most from triple
therapy were women, patients aged older than 65 years, and
patients with diabetes.
Conclusions: Triple antiplatelet therapy seems to be superior to
dual antiplatelet therapy in patients with ACS undergoing PCI with
drug-eluting stents with insigniﬁcant difference in adverse effect
proﬁle.
Cardiac arrhythmia early after ST
elevation myocardial infarction
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Sudden cardiac death is the most feared outcome of ST elevation
myocardial infarction (STEMI). Major cardiac arrhythmia occurring
very early after STEMI are harbinger of sudden cardiac death (SCD).
We conducted a study to record cardiac arrhythmia within 3 h of
thrombolysis in 100 patients of STEMI by applying 24 h Holter
recording. The patient admitted to ICCU were clinically examined,
thrombolysed with tenecteplase or streptokinase, put on 24 h
Holter monitoring and studied for major adverse coronary events
(MACE) during hospital stay and up to 1 month after discharge.
Mean age of study population was 56.75  15.6 yrs with male (76%)
predominating. One ormoremajor cardiac risk factor was noted in
74% patients with chronic smoking detected in 79%. Door to needle
time was 4.76  2.5 h. 59% had anterior location while 49% had
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